標題: Titlebook: Complement Therapeutics; John D. Lambris,V. Michael Holers,Daniel Ricklin Book 2013 Springer Science+Business Media New York 2013 infectio [打印本頁] 作者: 到來 時間: 2025-3-21 19:38
書目名稱Complement Therapeutics影響因子(影響力)
書目名稱Complement Therapeutics影響因子(影響力)學科排名
書目名稱Complement Therapeutics網(wǎng)絡公開度
書目名稱Complement Therapeutics網(wǎng)絡公開度學科排名
書目名稱Complement Therapeutics被引頻次
書目名稱Complement Therapeutics被引頻次學科排名
書目名稱Complement Therapeutics年度引用
書目名稱Complement Therapeutics年度引用學科排名
書目名稱Complement Therapeutics讀者反饋
書目名稱Complement Therapeutics讀者反饋學科排名
作者: 種屬關(guān)系 時間: 2025-3-21 21:26 作者: 北極熊 時間: 2025-3-22 01:15 作者: 鉤針織物 時間: 2025-3-22 06:59 作者: flaggy 時間: 2025-3-22 09:12
https://doi.org/10.1057/9780230349414ex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The bind作者: 爭吵 時間: 2025-3-22 15:22
Captivating Quanzhou Specialties,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1作者: 爭吵 時間: 2025-3-22 18:14 作者: Culpable 時間: 2025-3-22 23:18 作者: Contend 時間: 2025-3-23 02:18
Janine O. Ilagan,Melissa S. Juricand (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove作者: 惰性氣體 時間: 2025-3-23 05:50
Klaus B?hmer,Günter Meinardus,Walter SchemppPNH was an appropriate medical condition to develop and to investigate therapeutical complement inhibitors. Indeed, the first complement inhibitor eculizumab, a humanized anti-C5 monoclonal antibody, has been proven safe and effective for the treatment of PNH patients. Chronic treatment with eculizu作者: 現(xiàn)代 時間: 2025-3-23 10:09
Franz-Jürgen Delvos,Walter Schempp the alterative pathway of complement system, which constitutes a significant part of innate immunity in humans. Histologically, the hallmark observation is the isolated glomerular deposition of C3 complement in the absence of immune complexes. It is considered one of the C3 glomerulopathies, and it作者: inflame 時間: 2025-3-23 14:50 作者: FIS 時間: 2025-3-23 19:10 作者: Adornment 時間: 2025-3-23 22:31
https://doi.org/10.1007/978-94-015-8169-1ion; this is an ideal model for parsing the role of airway vasculature in rejection. Prior to the development of airway fibrosis in rejecting tracheal allografts, C3 deposits on the vascular endothelium just as tissue hypoxia is first detected. With the eventual destruction of vessels, microvascular作者: SMART 時間: 2025-3-24 02:45 作者: GEM 時間: 2025-3-24 06:41 作者: Fretful 時間: 2025-3-24 14:27
Mixed Convolutions and Zak Transforms,on with a recombinant protein that contains the C3d-binding region of complement receptor (CR) 2. Iron-oxide nanoparticles darken (negatively enhance) images obtained by T2-weighted MRI. We have demonstrated that the CR2-targeted nanoparticles bind within the kidneys of mice with lupus-like kidney d作者: 一個攪動不安 時間: 2025-3-24 16:45
Progress and Trends in Complement Therapeutics,l disorders involving abnormal complement activity or regulation, which include both acute and chronic diseases and affect a wide range of organs, diverse yet specifically tailored therapeutic approaches may be needed to shift complement back into balance. This chapter highlights the key changes in 作者: Consensus 時間: 2025-3-24 22:51
Inhibition of the Serine Proteases of the Complement System,mall-molecule drugs can be very efficient serine protease inhibitors, but they usually lack sufficient specificity. A promising approach to yield more specific compounds is the alteration of natural protease inhibitors through engineering or directed evolution resulting in new variants with fine-tun作者: dominant 時間: 2025-3-25 01:47
The Role of MASP-1/3 in Complement Activation,le to convert the proenzyme of Df to an active form in vitro. In addition, MASP-1 was able to activate MASP-2 and MASP-3 as C1r activates C1s. Thus, MASP-1 and MASP-3 seem to be involved in activation of both the lectin and alternative pathways.作者: 荒唐 時間: 2025-3-25 04:54 作者: cogent 時間: 2025-3-25 10:01 作者: 說不出 時間: 2025-3-25 12:52
Targeting gC1qR Domains for Therapy Against Infection and Inflammation,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1作者: 討厭 時間: 2025-3-25 17:33 作者: overshadow 時間: 2025-3-25 21:19
The Effects of Selective Complement and CD14 Inhibition on the ,-Induced Tissue Factor mRNA Upregulo effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced .-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 effic作者: Abbreviate 時間: 2025-3-26 00:51
CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Snd (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove作者: 津貼 時間: 2025-3-26 04:44 作者: LEER 時間: 2025-3-26 09:07
C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Fin the alterative pathway of complement system, which constitutes a significant part of innate immunity in humans. Histologically, the hallmark observation is the isolated glomerular deposition of C3 complement in the absence of immune complexes. It is considered one of the C3 glomerulopathies, and it作者: 語言學 時間: 2025-3-26 13:30 作者: 職業(yè) 時間: 2025-3-26 18:19
Innate Immunity as Orchestrator of Bone Marrow Homing for Hematopoietic Stem/Progenitor Cells,onsiveness of transplanted HSPCs to stroma-derived factor-1 (SDF-1) gradient. Furthermore, damaged BM cells release several other chemoattractants for HSPCs such as bioactive lipids sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) and chemotactic purines (ATP and UTP). In this chapter, w作者: 癡呆 時間: 2025-3-26 23:03 作者: BRAVE 時間: 2025-3-27 04:31 作者: grotto 時間: 2025-3-27 06:28
Evaluation of the Blood Compatibility of Materials, Cells, and Tissues: Basic Concepts, Test Modelsluation of the biocompatibility of materials and therapeutic cells and tissues. The use of different anticoagulants and specific inhibitors in order to be able to dissect interactions between the different cascade systems and cells of the blood is discussed. In addition, we describe two clinically r作者: Directed 時間: 2025-3-27 11:01 作者: TAP 時間: 2025-3-27 16:54
0065-2598 ve treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials..?.The chapters in this book cover a wide range of topics related to th978-1-4899-7823-3978-1-4614-4118-2Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: 異端 時間: 2025-3-27 19:44
Book 2013ight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials..?.The chapters in this book cover a wide range of topics related to th作者: STANT 時間: 2025-3-28 00:06
Defective Complement Action and Control Defines Disease Pathology for Retinal and Renal Disorders a作者: hypnotic 時間: 2025-3-28 04:15
0065-2598 earch and showcases methods developed and perfected in the l.This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and i作者: 硬化 時間: 2025-3-28 06:51 作者: 躺下殘殺 時間: 2025-3-28 13:29
Complement-Targeted Therapeutics in Periodontitis,s of the various complement components and pathways in periodontitis have only recently started to be elucidated. In this chapter, we review recent progress in the field and discuss the potential of complement-targeted therapeutics in the treatment of periodontitis.作者: 感激小女 時間: 2025-3-28 17:23
Book 2013cations. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as作者: 整體 時間: 2025-3-28 21:17
Progress and Trends in Complement Therapeutics,en by promising experiences with the first marketed complement drugs, increased knowledge about the involvement of complement in health and disease, and improvements in structural and analytical techniques as well as animal models of disease, the field has seen a surge in creative approaches to ther作者: 男生戴手銬 時間: 2025-3-29 02:04 作者: Dignant 時間: 2025-3-29 03:08 作者: helper-T-cells 時間: 2025-3-29 08:25
Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for Sd importance of complement inhibitors as therapeutics. Systemic lupus erythematosus is a prototype of systemic autoimmune disorders. The disease, though rare, is potentially fatal and afflicts women at their reproductive age. It is a complex disease with multiorgan involvement, and each patient pres作者: Loathe 時間: 2025-3-29 15:13
,DAF as a Therapeutic Target for Steroid Hormones: Implications for Host–Pathogen Interactions, implication of steroid hormone treatment on multiple pathologies, including infection and the host–pathogen interactions. DAF/CD55 plays multiple physiologic functions including tissue protection from the cytotoxic complement injury, an anti-inflammatory function due to its anti-adherence propertie作者: Mitigate 時間: 2025-3-29 16:17 作者: urethritis 時間: 2025-3-29 19:45
The Alternative C5a Receptor Function,efore, the neutrophil C5a receptor (C5aR) is believed to be a member of the pro-inflammatory receptors. However, C5aR deficiency endows mouse neutrophils with increased sensitivity to .. We have demonstrated that C5aR accepts not only C5a but also ribosomal protein S19 (RP S19) oligomers. RP S19 oli作者: Lasting 時間: 2025-3-30 01:26
The Effects of Selective Complement and CD14 Inhibition on the ,-Induced Tissue Factor mRNA Upreguled tissue factor (TF) mRNA upregulation, expression by monocytes, and functional activity in human whole blood. .: Whole . bacteria were incubated for up to 4 h in human whole blood containing the anticoagulant lepirudin, which does not affect complement activation. TF mRNA levels were analyzed usin作者: Visual-Field 時間: 2025-3-30 06:30
CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Sd biopharmaceutical interest in developing drugs that modulate the complement system. Substantial challenges remain, however, that must be overcome before widespread application of complement inhibitors in inflammatory and autoimmune diseases becomes possible. Among these challenges are the followin作者: ESO 時間: 2025-3-30 11:22
Paroxysmal Nocturnal Hemoglobinuria and the Complement System: Recent Insights and Novel Anticomplearrow failure. PNH is due to a somatic, acquired mutation in the X-linked . gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 and CD59. The most evident clinical manifestations of PNH arise from dysregulated compleme作者: Anthropoid 時間: 2025-3-30 13:00 作者: eulogize 時間: 2025-3-30 20:35 作者: SLAY 時間: 2025-3-31 00:46 作者: 泄露 時間: 2025-3-31 00:52
Innate Immunity as Orchestrator of Bone Marrow Homing for Hematopoietic Stem/Progenitor Cells,diochemotherapy. This eliminates hematolymphopoietic cells and at the same time damages hematopoietic microenvironment in bone marrow (BM). The damage of BM tissue leads to activation of complement cascade (CC), and bioactive CC cleavage fragments modulate several steps of BM recovery after transpla作者: 懶鬼才會衰弱 時間: 2025-3-31 07:54
Complement-Mediated Microvascular Injury Leads to Chronic Rejection,es not undergo primary systemic arterial revascularization at the time of surgery, lung transplants rely on the establishment of a microcirculation and are especially vulnerable to the effects of microvascular loss. Microangiopathy, with its attendant ischemia, can lead to tissue infarction and airw作者: 難解 時間: 2025-3-31 09:24 作者: monologue 時間: 2025-3-31 15:21 作者: 序曲 時間: 2025-3-31 20:48 作者: 等級的上升 時間: 2025-4-1 01:37 作者: 魔鬼在游行 時間: 2025-4-1 02:05 作者: grudging 時間: 2025-4-1 08:15
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/c/image/231284.jpg
